Docteur Elodie RIVIÈRE

Thèses universitaires

• Rôle des cellules épithéliales salivaires au cours du Syndrome de Sjögren primitif

  2020

  Role of salivary gland epithelial cells in primary Sjögren’s Syndrome

  Immunologie🎓 université Paris-Saclay

  Direction : Xavier Mariette, Gaetane Nocturne

Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.

Bibliographie

• Façonner le château de demain : entre héritage du passé et appropriation patrimoniale : le cas du château de Lavardens

  2024

  Thèse

• m 6 A RNA methylation controls salivary gland epithelial cell function and has a protective role in Sjögren’s disease

  2024

  ArticleAnnals of the Rheumatic Diseases

• Liposomal AntagomiR‐155‐5p restores anti‐inflammatory macrophages and improves arthritis in pre‐clinical models of Rheumatoid arthritis

  2023

  ArticleArthritis & rheumatology

• Salivary gland epithelial cells from patients with Sjögren's syndrome induce B-lymphocyte survival and activation

  2020

  ArticleAnnals of the Rheumatic Diseases

• Rôle des cellules épithéliales salivaires au cours du Syndrome de Sjögren primitif

  2020

  Thèse

• Myositis as a manifestation of SARS-CoV-2

  2020

  ArticleAnnals of the Rheumatic Diseases

• Interleukin‐7/Interferon axis drives T‐cell and salivary gland epithelial cell interactions in Sjögren’s syndrome

  2020

  ArticleArthritis & rheumatology

• Dietary fibers in osteoarthritis: What are the evidences?

  2019

  ArticleJoint Bone Spine

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieux de consultation

• GHU APHP HU PSSD SITE JEAN VERDIER

  Avenue DU 14 JUILLET, 93143 Bondy

  ☎ 0148026666Hospitalier🏥 Voir cet établissement

• GHU APHP HU PSSD SITE AVICENNE

  125 Rue DE STALINGRAD, 93009 Bobigny

  ☎ 0148955585Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

  Annals of the rheumatic diseases · 2020

  📚 158 citations🎯 RCR 8.46Top 3% NIH🔓 Open Access📄 PDF gratuit ↗
• 2

  Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey

  Arthritis & rheumatology (Hoboken, N.J.) · 2017

  📚 119 citations🎯 RCR 6.36Top 5% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  ObjectiveData on adult IgA vasculitis (Henoch‐Schönlein) (IgAV) are scarce. This survey was designed to better define the clinical spectrum of IgAV and efficacy of treatments in a French patient population.MethodsData on clinical characteristics, histologic features, and treatment response from 260 patients with IgAV included in a French multicenter retrospective survey were analyzed. Efficacy data were compared using different statistical models.ResultsThe mean ± SD age of the patients with IgAV at diagnosis was 50.1 ± 18 years, and 63% of patients were male. Baseline manifestations included purpura (100%), arthralgias/arthritis/myalgia (61%), glomerulonephritis (70%), and/or gastrointestinal involvement (53%). Thirty percent of patients showed renal failure at baseline. In univariate analysis, the response to therapy was 80% (64 of 80) in patients treated with corticosteroids (CS) alone, compared to 77% (23 of 30) in patients treated with CS plus cyclophosphamide (CYC) and 59% (10 of 17) in patients treated with colchicine (P = 0.17). Multivariable analysis showed that treatment with CS or CS plus CYC was more effective than colchicine in achieving a response. Efficacy differences were demonstrated using different statistical models: in the multivariable logistic regression model, odds ratio (OR) 3.68, 95% confidence interval (95% CI) 1.10–12.33 (P = 0.03); in the inverse probability weighting on propensity score model, OR 3.75, 95% CI 1.28–10.99 (P = 0.02). The efficacy of CS plus CYC as compared to CS alone was discordant according to the analytic method used. Analysis with the multivariable logistic regression model did not demonstrate a difference between CS plus CYC and CS alone (OR 0.88, 95% CI 0.29–2.67; P = 0.82). In contrast, inverse probability weighting on propensity score showed that CS plus CYC was more effective than CS alone (OR 1.79, 95% CI 1.00–3.20; P = 0.049).ConclusionThis series constitutes the largest series of adults with IgAV reported in the literature so far. It provides data on clinical and histologic presentation and therapeutic efficacy, suggesting that CS alone appears to be a reasonable first‐line therapy in patients with IgAV, while the benefit of adding CYC to CS remains uncertain.

• 3

  Myositis as a manifestation of SARS-CoV-2

  Annals of the rheumatic diseases · 2021

  📚 102 citations🎯 RCR 7.33Top 4% NIH

Publications scientifiques (34) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

  Collection2016Figshare

  Abstract Background Recent works have suggested a possible link between interleukin (IL)-33 and B-cell biology. We aimed to study the possible association between serum IL-33 detection and response to rituximab (RTX) in

• Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

  Collection2016Figshare

  Abstract Background Recent works have suggested a possible link between interleukin (IL)-33 and B-cell biology. We aimed to study the possible association between serum IL-33 detection and response to rituximab (RTX) in

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche